SNY logo

SANOFI-ADR

SNYNASDAQ
πŸ† #141 by market capEarnings Oct 30 Β· PreUS Equity
$42.24β–² $0.35 (+0.84%)
After hours Β· at close
πŸ””
Track SNY
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.8%
7dβ–² 3.1%
14dβ–² 6.2%
30dβ–² 2.6%
ytdβ–Ό 12.8%
1yβ–Ό 17.3%
🏦Market Cap
$51.02B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
13.4%
Healthy
πŸ“ŠGross Margin
72.8%
High
πŸ’΅FCF Margin
14.5%
Healthy
βš–οΈP/S Ratio
1.8x
Cheap
Otter Score
84
Strong

Trading Snapshot

Day Range
$41.65 – $42.27
52-Week Range
β€”
Volume (shares)
199,025
Avg Volume (shares)
β€”
Shares Outstanding
1.21B
Next Earnings
2026-10-30

Fundamentals Snapshot

Annual Revenue
$46.72B
Last Q Revenue
$12.30B
P/E Ratio
22.5
P/S Ratio
1.8x
EPS (TTM)
β€”
Dividend Yield
10.90%
Dilution (1yr)
βˆ’2.6%
SNY logo

SANOFI-ADR

SNY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$46.7Bβ–² +5.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
72.1%β–² +2.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$9.6Bβ–² +32.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$10.1Bβ–² +72.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.44Bβ–Ό βˆ’2.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$12.7Bβ–Ό βˆ’$2.2B YoY
StockOtter Β· stockotter.space

About SANOFI-ADR

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
84/100

Analyst Ratings

β“˜
Consensus
Buy
31 analysts
Strong Buy7
Buy10
Hold13
Sell1
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.